Literature DB >> 15995133

Bisphosphonates in orthopaedic surgery.

Carol D Morris1, Thomas A Einhorn.   

Abstract

Bisphosphonates are the most clinically important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption. Currently, seven bisphosphonates have the approval of the United States Food and Drug Administration. The most common adult diseases treated with bisphosphonates include osteoporosis, Paget disease, and metastatic bone disease. The treatment of pediatric disorders such as osteogenesis imperfecta and fibrous dysplasia with bisphosphonates has gained momentum, and initial investigations have demonstrated an acceptable safety profile. Currently, there is a lack of long-term follow-up data, which will be necessary for the development of responsible guidelines for therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995133     DOI: 10.2106/JBJS.D.03032

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  14 in total

Review 1.  Orthobiologics in the augmentation of osteoporotic fractures.

Authors:  J Tracy Watson; Daemeon A Nicolaou
Journal:  Curr Osteoporos Rep       Date:  2015-02       Impact factor: 5.096

2.  Can an anti-fracture agent heal fractures?

Authors:  Thomas A Einhorn
Journal:  Clin Cases Miner Bone Metab       Date:  2010-01

3.  Fracture healing and drug therapies in osteoporosis.

Authors:  Amy Hoang-Kim; Letizia Gelsomini; Deianira Luciani; Antonio Moroni; Sandro Giannini
Journal:  Clin Cases Miner Bone Metab       Date:  2009-05

Review 4.  Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review.

Authors:  Umberto Tarantino; Ida Cariati; Chiara Greggi; Riccardo Iundusi; Elena Gasbarra; Giovanni Iolascon; Andreas Kurth; Kristina E Akesson; Mary Bouxsein; Paolo Tranquilli Leali; Roberto Civinini; Francesco Falez; Maria Luisa Brandi
Journal:  Osteoporos Int       Date:  2022-07-18       Impact factor: 5.071

5.  The role of bone mineral density in adult spinal deformity patients undergoing corrective surgery: a matched analysis.

Authors:  Syed I Khalid; Ravi S Nunna; Jennifer S Smith; Rachyl M Shanker; Alecia A Cherney; Kyle B Thomson; Sai Chilakapati; Ankit I Mehta; Owoicho Adogwa
Journal:  Acta Neurochir (Wien)       Date:  2022-08-04       Impact factor: 2.816

6.  Bisphosphonate-induced atypical subtrochanteric femoral fracture.

Authors:  Raju Vaishya; Abhishek Vaish; Arshad Nadeem
Journal:  BMJ Case Rep       Date:  2013-11-28

7.  Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.

Authors:  T Matsunaga; M Shigetomi; T Hashimoto; H Suzuki; T Gondo; H Tanaka; T Sugiyama; T Taguchi
Journal:  Osteoporos Int       Date:  2007-05-10       Impact factor: 4.507

Review 8.  Radiographic and functional outcomes of bisphosphonate use in lumbar fusion: a systematic review and meta-analysis of comparative studies.

Authors:  Nickolas Fretes; Evan Vellios; Akshay Sharma; Remi M Ajiboye
Journal:  Eur Spine J       Date:  2019-08-05       Impact factor: 3.134

9.  Heterotopic ossification after central nervous system trauma: A current review.

Authors:  M P Sullivan; S J Torres; S Mehta; J Ahn
Journal:  Bone Joint Res       Date:  2013-03-01       Impact factor: 5.853

10.  [Use of bisphosphonates in orthopedic surgery].

Authors:  R Bartl; C Bartl; R Gradinger
Journal:  Orthopade       Date:  2008-06       Impact factor: 1.004

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.